Could cause temporary or reversible harm; serious harm is unlikely.
Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
| Brand name | RAMIPRIL |
| Generic name | RAMIPRIL |
| Active ingredient(s) | RAMIPRIL |
| Distributed by / for | Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432 |
| NDC | 76282-673-01 |
| Full product label | Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bottles, Rx only, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432, Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228. |
| Recalling firm | Hikma Pharmaceuticals USA INC. |
| Distribution | Nationwide within the United States |
| Quantity | a) 25,970 bottles; b) 2,384 bottles |
| Recall initiated | 2026-08-24 |
| Report date | 2026-09-02 |
| Recall completed | — |
| Recall number | D-0831-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Columbus OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗